Core Viewpoint - The journey of Sinovation has shifted from a grand vision of building an "innovative pharmaceutical empire" to facing harsh realities, particularly after the termination of a significant acquisition deal, leading to a deteriorating financial situation and challenges in the Hong Kong IPO market [1][2]. Group 1: Company Transformation and Challenges - Sinovation, initially a functional raw material producer, aimed to transform into an innovative pharmaceutical company by acquiring assets in cutting-edge fields like ADC and mRNA vaccines [1]. - The planned acquisition of Shiyao Baike for 7.6 billion yuan was halted due to a drastic price drop of its core product, "Jin You Li," from approximately 1,600 yuan to about 666 yuan, alongside stagnant sales and increased market competition [1]. - The anticipated GLP-1 weight loss drug pipeline lacks competitive advantages, failing to fill the revenue gap [1]. Group 2: Financial Deterioration - The cessation of external funding from the halted acquisition has led to a rapid decline in Sinovation's financial health, characterized by a struggling caffeine business and escalating R&D costs, which surged by 81% year-on-year in the first half of 2025 [2]. - The IPO in Hong Kong is perceived more as a necessity to address a significant funding gap rather than a strategic global expansion [2]. Group 3: Market Environment and IPO Challenges - Sinovation's IPO faces a challenging market environment, with a rising post-listing failure rate of 42.10% since November, compared to 30.23% in the first half of 2025 and 35.71% for the entire year of 2024, indicating a shift towards selective investment by investors [3]. - The valuation conflict in the "A+H" model poses a significant challenge, as Hong Kong investors prioritize cash flow and dividend returns, while Sinovation is currently unprofitable with negative cash flow [3]. Group 4: Liquidity Concerns and Funding Utilization - New IPO regulations in Hong Kong allow issuers to set public offering ratios between 10% and 60%, leading to potential liquidity issues as over 90% of shares may be concentrated among a few cornerstone and institutional investors [4]. - The ambiguity surrounding the use of funds raised from the IPO raises concerns about whether they will be effectively utilized for breakthrough projects or diluted across broad R&D investments [5][6]. Group 5: Future Prospects and Commercialization Challenges - The future value of Sinovation hinges on its ability to commercialize its innovative drug pipeline, with existing products lacking competitive advantages and future prospects in ADC and mRNA vaccine platforms facing intense competition [6]. - Successfully entering the Hong Kong market is only the first step; the real challenge lies in demonstrating to a more rational international market that the company is not only in need of funds but also worthy of investment [6].

Core Viewpoint - CSPC Innovation Pharmaceutical Co., Ltd. (formerly known as CSPC New Drug Co., Ltd.) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, aiming to leverage its strong market position in the biopharmaceutical and health supplement sectors [2][18]. Company Overview - Established in 2006, CSPC Innovation focuses on research, development, and manufacturing of biopharmaceuticals, functional raw materials, and health supplements, positioning itself as a leader in the health sector [3][19]. - The company is the world's largest producer of synthetic caffeine, supplying major beverage companies like Coca-Cola, PepsiCo, and Red Bull, with products distributed in over 65 countries [3][19]. Business Expansion - In 2016, CSPC Innovation expanded into the health supplement market, offering a diverse range of products aimed at enhancing immunity, improving bone density, and providing antioxidant support [4][20]. - The acquisition of 100% of CSPC Saint Snow in 2022 allowed the company to diversify its product offerings to include other functional raw materials, such as acarbose and anhydrous glucose [4][20]. Biopharmaceutical Development - In 2024, CSPC Innovation gained control of Giant Bio, marking its entry into the biopharmaceutical sector with a focus on innovative therapies targeting unmet clinical needs in oncology, autoimmune diseases, and infectious diseases [5][21]. - The company has commercialized two antibody drugs and developed mRNA vaccines, including the first domestically developed COVID-19 mRNA vaccine in China [5][21]. Research and Development Pipeline - CSPC Innovation has 15 drugs in clinical or late-stage development, including 9 antibody-drug conjugates (ADCs) and 1 mRNA vaccine, targeting high-incidence cancers and other significant unmet medical needs [6][22]. - The ADC pipeline focuses on indications such as lung cancer, breast cancer, gastric cancer, colorectal cancer, and esophageal squamous cell carcinoma, with key targets including EGFR and HER2 [6][22]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first seven months of 2025 were approximately RMB 2.84 billion, RMB 2.54 billion, RMB 1.98 billion, and RMB 1.24 billion, respectively, with net profits showing a decline in 2024 and 2025 [12][13]. - The revenue breakdown indicates that functional raw materials and health supplements accounted for the majority of sales, while biopharmaceutical products contributed a smaller portion [12][13]. Shareholder Structure - Prior to the IPO, CSPC Innovation's major shareholders include CSPC Group, which holds approximately 75.30% of the shares, with the remaining 24.70% held by other A-share shareholders [9][25]. Management Team - The board of directors consists of 10 members, including 3 executive directors and 5 independent non-executive directors, ensuring a diverse governance structure [10][27].

Core Viewpoint - Shiyao Innovation Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor, marking a significant step in its corporate development strategy transformation [4]. Company Overview - Established in 2006, Shiyao Innovation focuses on the research, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods [4]. - The company was listed on the ChiNext board in 2019, with a current market capitalization of approximately 48 billion RMB [4]. - Shiyao Innovation has commercialized two antibody drugs and two mRNA vaccines, with a robust pipeline of 15 drugs in clinical or late-stage development, including 9 ADC drugs and 1 mRNA vaccine [4]. Market Position - According to Frost & Sullivan, Shiyao Innovation has maintained its position as the world's largest producer of chemically synthesized caffeine by revenue and shipment volume from 2020 to 2024 [4]. Strategic Developments - In 2024, Shiyao Innovation acquired control of Jushi Biopharmaceuticals, expanding its main business into the biopharmaceutical sector, which is a key milestone in its strategic transformation [4]. - The company plans to acquire an additional 29% stake in Jushi Biopharmaceuticals from Enbipu Pharmaceuticals for a cash consideration of 1.1 billion RMB, increasing its ownership to 80% [5]. Financial Performance - For the fiscal years 2022, 2023, and the first seven months of 2024, Shiyao Innovation reported revenues of 2.838 billion RMB, 2.539 billion RMB, and 1.981 billion RMB, respectively [6]. - The company's profits for the same periods were 293.85 million RMB, 125.67 million RMB, and a loss of 303.71 million RMB [6]. - The revenue and profit trends indicate a decline, with a significant loss projected for 2024 [6]. Shareholding Structure - As of the last practicable date, Enbipu Pharmaceuticals holds approximately 75.30% of Shiyao Innovation's issued shares, with 74.47% directly held and 0.83% indirectly through its wholly-owned subsidiary [7]. - Enbipu Pharmaceuticals is owned by Jiaxi and Shiyao Group, with respective ownership stakes of 45.94% and 54.06% [7].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.05% to 25,528.85 points, the Hang Seng Tech Index down by 0.81% to 5,535.64 points, and the National Enterprises Index decreasing by 0.23% to 8,933.69 points [1] - Major technology stocks showed mixed performance, with Alibaba down 1.5%, Tencent up 0.17%, JD.com down 0.44%, Xiaomi up 0.91%, Meituan up 0.8%, Kuaishou down 0.15%, and Bilibili down 0.1% [1] - Chip stocks declined significantly, with ZTE Corporation down 13.08%, Hua Hong Semiconductor down 4.8%, and Shanghai Fudan down 2.55% [1] - The pharmaceutical sector also faced losses, with Sihuan Pharmaceutical down over 7% and Genscript Biotech down over 5% [1] - Wind power stocks led the gains, with Goldwind up over 5% and Dongfang Electric up over 4% [1] - Solar energy stocks generally fell, with GCL-Poly Energy down over 7% [1] Company News - Sunny Optical Technology (02382.HK) reported a mobile lens shipment of approximately 119 million units in November, a month-on-month decrease of 2.3% but a year-on-year increase of 7.5% [2] - Q Technology (01478.HK) saw its mobile camera module sales drop to 38.05 million units in November, down 13.6% month-on-month and 5.6% year-on-year [2] - Yuanyuan Group (00551.HK) reported a net operating income of approximately $660 million in November, a decrease of 3.1% year-on-year [2] - Baoshan International (03813.HK) reported a net operating income of 1.172 billion yuan in November, down 5.1% year-on-year [3] - Morning News Technology (02000.HK) reported an unaudited revenue of 44.3 million HKD in November, up 48.4% month-on-month and 19.73% year-on-year [4] - Ocean Group (03377.HK) reported a cumulative contract sales of approximately 23.79 billion yuan over the first 11 months [5] - Jianye Real Estate (00832.HK) reported a total property contract sales of 7.168 billion yuan over the first 11 months, down 16.3% year-on-year [6] - Yuzhou Group (01628.HK) reported a cumulative sales amount of 6.196 billion yuan over the first 11 months [7] - COFCO Joycome (01610.HK) reported a pig slaughter volume of 559,000 heads in November, a month-on-month decrease of 4.44% [8] - CSPC Pharmaceutical Group (01093.HK) received clinical trial approval in the U.S. for its fully human anti-ACTRIIA/IIB monoclonal antibody (JMT206) [9] - China Digital Technology (01796.HK) entered into a strategic cooperation agreement with Xinhua Pharmaceutical [10] - China Hongqiao (01378.HK) received approval from the Shenzhen Stock Exchange for the acquisition of Hongtu Industrial [11] - CICC (03908.HK) plans to issue perpetual subordinated bonds not exceeding 3 billion yuan [12] Institutional Insights - Everbright Securities noted that compared to previous bull markets, the current index still has significant upside potential, but the duration of the bull market may be more important than the magnitude of the increase [13] - Guosen Securities indicated that the recent adjustments in the Hong Kong market could open up space for a market rally in 2026, with over 110 billion yuan of net inflow from southbound funds in November [13] - CITIC Securities projected that the Hong Kong market will experience a second round of valuation recovery in 2026, focusing on sectors with performance certainty and valuation elasticity [14]

Investment Rating - The industry investment rating is "Outperform" compared to the market, indicating an expected performance greater than the CSI 300 index by more than 5% over the next six months [49]. Core Insights - Alnylam has shown strong revenue growth, with total revenue reaching $1.249 billion in Q3 2025, a year-over-year increase of 149%. Net product revenue was $851 million, up 103%, and revenue from collaborations and royalties surged by 393% to $398 million [2][7]. - The TTR product line is experiencing rapid growth, with Q3 2025 revenue of $724 million, a 135% increase year-over-year. The company has raised its full-year revenue guidance for TTR products to between $2.475 billion and $2.525 billion [16][29]. - Alnylam's research pipeline is robust, with seven drugs in Phase 3 clinical trials, including Nucresiran, which is expected to offer a better dosing regimen. The company is also exploring siRNA therapies in chronic disease areas [38][40]. Summary by Sections 1. Q3 2025 Performance Overview - In Q3 2025, Alnylam's total revenue was $1.249 billion, reflecting a 149% increase from the previous year. The net product revenue was $851 million, up 103%, while collaboration and royalty revenues reached $398 million, a 393% increase [2][7]. 2. Rapid Growth of TTR Products - The TTR product revenue for Q3 2025 was $724 million, marking a 135% year-over-year increase. The company has adjusted its full-year revenue guidance for TTR products to $2.475 billion to $2.525 billion, up from the previous estimate of $2.175 billion to $2.275 billion [16][29]. 3. Rich R&D Pipeline - Alnylam has a diverse R&D pipeline with seven drugs in Phase 3 trials. Nucresiran, a new generation TTR product, is expected to provide a more effective dosing schedule. The company is also advancing siRNA therapies in chronic disease management [38][40].

Group 1 - The core viewpoint of the report highlights that the pharmaceutical industry in China is experiencing a reversal in 2025, driven by innovative drugs, with significant benefits observed in the CXO and upstream supply chain sectors, particularly in the Hong Kong stock market where innovative drugs have seen a rise of over 80% year-to-date [1][4] - The report emphasizes that the core catalyst for innovative drugs comes from policy support and the realization of business development (BD) opportunities abroad, with notable transactions exceeding 1 billion USD, validating the international competitiveness of Chinese innovative drugs [1][2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, allowing for the inclusion of high-value innovative drugs in commercial insurance, addressing the gap in coverage for expensive treatments [1][2] Group 2 - The report indicates a rapid growth trend in the number of license-out transactions by Chinese pharmaceutical companies, with total upfront payments reaching 6.298 billion USD, a 53% year-on-year increase, and total transaction amounts reaching 118.862 billion USD, a 125% increase [2] - Looking ahead to 2026, the report suggests a shift from "BD-driven" to "data-driven" investment in innovative drugs, emphasizing the importance of clinical data validation and commercial capabilities for revenue growth [2] - Recommended stocks for investment include Heng Rui Medicine, Kelun-Biotech, and Teva Biopharmaceuticals, among others, while companies like Kangfang Biotech and Innovent Biologics are suggested for further attention [2][3] Group 3 - The overall profitability of the pharmaceutical sector remains stable, with a gradual improvement in the profitability of the pharmaceutical manufacturing industry, despite a slight decline in revenue growth [11][15] - The report notes a significant divergence within the industry, with the medical services sector performing well, while the profits of the biopharmaceutical sector have seen a substantial decline [28][29] - The report highlights that the medical insurance fund's income and expenditure growth rates are stabilizing, indicating a long-term trend towards cost control in medical insurance, which is essential for the sustainable development of the innovative drug industry [31][36]

智通财经APP讯，石药集团(01093)发布公告，于2025年12月10日，石药创新向联交所提交上市申请，以 申请H股建议上市。预期H股建议上市完成后，石药创新将仍为本公司之间接附属公司。 H股建议上市的完成尚须待(其中包括)完成中国证监会、联交所及证监会等相关政府及监管机构备案和 ╱或批准。本公司将于适当时候进一步更新H股建议上市之进展。 ...

H股建议上市的完成尚须待(其中包括)完成中国证监会、联交所及证监会等相关政府及监管机构备案和 ╱或批准。本公司将于适当时候进一步更新H股建议上市之进展。 石药集团(01093)发布公告，于2025年12月10日，石药创新向联交所提交上市申请，以申请H股建议上 市。预期H股建议上市完成后，石药创新将仍为本公司之间接附属公司。 ...

Market Overview - The Hong Kong stock market opened high but experienced fluctuations, with the Hang Seng Index up 0.09% at 25,563.05 points, while the Tech Index fell 0.65% to 5,544.57 points [1] - Major tech stocks showed mixed performance, with Alibaba down 0.78%, Tencent down 0.08%, and JD.com down 0.44%, while Xiaomi rose 0.81% and Meituan increased by 0.8% [1] - Lithium battery stocks performed well, with CATL rising over 2%, while chip stocks weakened, with ZTE down over 9% [1] Company News - Sunny Optical Technology (02382.HK) reported November mobile lens shipments of approximately 119 million units, a month-on-month decrease of 2.3% but a year-on-year increase of 7.5% [2] - Q Technology (01478.HK) saw November mobile camera module sales of 38.05 million units, down 13.6% month-on-month and down 5.6% year-on-year [2] - Yuanyuan Group (00551.HK) reported a net operating income of approximately $660 million in November, a year-on-year decrease of 3.1% [2] - Baoshan International (03813.HK) reported a net operating income of 1.172 billion yuan in November, down 5.1% year-on-year [3] - Morning News Technology (02000.HK) reported unaudited revenue of 44.3 million HKD in November, up 48.4% month-on-month and 19.73% year-on-year [4] - Ocean Group (03377.HK) reported a cumulative contract sales amount of approximately 23.79 billion yuan for the first 11 months [5] - Jianye Real Estate (00832.HK) reported a total property contract sales amount of 7.168 billion yuan for the first 11 months, a year-on-year decrease of 16.3% [6] - Yuzhou Group (01628.HK) reported a cumulative sales amount of 6.196 billion yuan for the first 11 months [7] - COFCO Joycome (01610.HK) reported a pig slaughtering volume of 559,000 heads in November, a month-on-month decrease of 4.44% [8] - CSPC Pharmaceutical Group (01093.HK) received clinical trial approval in the U.S. for its fully human anti-ACTRIIA/IIB monoclonal antibody (JMT206) [9] - China Digital Technology (01796.HK) entered into a strategic cooperation agreement with Xinhua Pharmaceutical [10] - China Hongqiao (01378.HK) announced that the acquisition of Hongtu Industrial by Hongchuang Holdings was approved by the Shenzhen Stock Exchange's M&A Review Committee [11] - CICC (03908.HK) plans to issue perpetual subordinated bonds of no more than 3 billion yuan [12] Institutional Insights - Everbright Securities noted that compared to previous bull markets, the current index has significant upside potential, but the duration of the bull market may be more important than the magnitude of the increase [13] - Guosen Securities indicated that the recent adjustments in the Hong Kong market could open up space for a market rise in 2026, with over 110 billion yuan of net inflow from southbound funds in November [13] - CITIC Securities predicted a second round of valuation recovery for the Hong Kong market in 2026, emphasizing the need to focus on "earnings certainty + valuation elasticity" in sectors like technology, pharmaceuticals, resources, and essential consumption [13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 H股建議上市之完成尚須待（ 其中包括 ）完成中國證監會、聯交所及證監會等相關政府及監 管機構備案和╱或批准。本公司將於適當時候進一步更新H股建議上市之進展。 石 藥 創 新 向 聯 交 所 遞 交 之 上 市 文 件 申 請 版 本 之 經 編 纂 版 本（「 申 請 版 本 」）可 於 聯 交 所 網 站 https: / / www1.hkexnews.hk / app / appindex.html下載。申請版本載有（ 其中包括 ）有關石藥創新集 團之若干業務及財務資料。股東及本公司潛在投資者應留意，申請版本為草擬本，當中所 載資料並不完整，且可能會有重大變動。 – 1 – 股東及本公司潛在投資者務請注意，H股建議上市須視乎（ 其中包括）現行市況及向有關當 局（包括中國證監會、聯交所及證監會）備案和 ...